Matthew E. Korenberg - May 13, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President & Chief Operating
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
Stock symbol
LGND
Transactions as of
May 13, 2024
Transactions value $
-$1,495,740
Form type
4
Date filed
5/15/2024, 07:34 PM
Previous filing
Feb 29, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Sale -$291K -3.44K -3.31% $84.54 100K May 13, 2024 Direct F1
transaction LGND Common Stock Sale -$1.16M -13.6K -13.58% $85.08 86.8K May 14, 2024 Direct F2
transaction LGND Common Stock Sale -$44.6K -520 -0.6% $85.68 86.3K May 14, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.5000 to $84.8750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.5950 to $85.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.6250 to $85.7650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.